Letter to the Editor Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Dec 26, 2024; 16(12): 1110-1114
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1110
Interplay and therapeutic implications of colorectal cancer stem cells, tumor microenvironment, and gut microbiota
Hui Zhang, Department of Emergency Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Bo-Tao Xu, Department of Cardiothoracic Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Di-Ping Luo, Tie-Fei He, Department of Vascular Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
ORCID number: Hui Zhang (0009-0008-5987-6193); Bo-Tao Xu (0000-0002-4275-0489); Di-Ping Luo (0009-0009-0029-2035); Tie-Fei He (0009-0007-4252-6835).
Author contributions: Zhang H contributed to the conceptualization, writing, reviewing and editing of this manuscript; Xu BT wrote the original draft; Luo DP participated in the formal analysis; He TF contributed to the methodology. All authors participated in drafting the manuscript and all authors have read, contributed to, and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Zhang, Department of Emergency Surgery, Zhuji People’s Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. 13867588467@163.com
Received: September 24, 2024
Revised: October 17, 2024
Accepted: December 3, 2024
Published online: December 26, 2024
Processing time: 79 Days and 22.4 Hours

Abstract

This article discusses the interplay between colorectal cancer (CRC) stem cells, tumor microenvironment (TME), and gut microbiota, emphasizing their dynamic roles in cancer progression and treatment resistance. It highlights the adaptability of CRC stem cells, the bidirectional influence of TME, and the multifaceted impact of gut microbiota on CRC. The manuscript proposes innovative therapeutic strategies focusing on these interactions, advocating for a shift towards personalized and ecosystem-targeted treatments in CRC. The conclusion underscores the importance of continued research in these areas for developing effective, personalized therapies.

Key Words: Colorectal cancer; Stem cells; Tumor microenvironment; Gut microbiota; Treatment resistance; Therapeutic strategies; Personalized medicine; Cancer ecosystem; Research advancements

Core Tip: The core objective of this article is to build upon the compelling arguments presented in the review, highlighting emerging trends, and introducing fresh perspectives to delve deeper into the intricacies of the interplay among these factors. A profound understanding of this interactive relationship is of paramount importance, as it holds the key to unlocking entirely new colorectal cancer treatment strategies and significantly improving patient prognosis.



TO THE EDITOR

The recent review in the World Journal of Stem Cells on the complex interplay among the tumor microenvironment (TME), gut microbiota, and the stemness of colorectal cancer (CRC) cells offers a profound insight into the evolving landscape of CRC research[1]. This article aims to build upon the compelling narrative presented in the review, highlighting emerging trends and offering novel perspectives that could further elucidate the intricate relationship between these factors. Understanding this interplay is crucial, as it holds the key to unlocking new therapeutic strategies and improving patient outcomes in CRC (Figure 1).

Figure 1
Figure 1 The schematic diagram of multi-cell-cell communication in colon epithelium and colon adenocarcinoma. Arrows indicate the activation interactions between different cells (left). Under the influence of intestinal microorganisms, carcinoma in situ may progress to invasive cancer (right).
Discussion on CRC stem cells

In addressing the complex nature of CRC stem cells, it’s crucial to emphasize their dynamic role in tumor progression and therapy resistance. Recent studies have unveiled that CRC stem cells are not a static entity but are highly influenced by their microenvironment[2-4]. This adaptive nature complicates treatment strategies, as these cells can evade conventional therapies by altering their characteristics. Moreover, the heterogeneity within the stem cell population in CRC presents an additional layer of complexity, necessitating a more nuanced approach in therapeutic development. Understanding the molecular mechanisms driving this plasticity is paramount for devising effective treatments that can target these elusive cells[5-7].

Role of the TME

The TME plays a pivotal role in the pathogenesis of CRC[8], particularly in how it shapes the behavior of CRC stem cells. The interplay between CRC stem cells and their microenvironment is a dance of mutual influence, where TME not only nurtures stem cells but also undergoes modifications instigated by these cells[9]. This bidirectional communication is key in understanding tumor progression and resistance to therapy. Recent research highlights the importance of TME components such as immune cells, stromal cells, and extracellular matrix in modulating CRC stem cell functions[10]. These insights offer new avenues for therapeutic intervention, targeting not just the cancer cells but also their supporting environment.

Impact of gut microbiota

The gut microbiota’s role in CRC has gained significant attention, providing new insights into cancer biology and potential treatment modalities[11-13]. Research indicates that the gut microbiota influences CRC development and progression, possibly through interactions with CRC stem cells and the TME[14]. These microorganisms can affect immune responses, metabolic pathways, and even genetic stability within the tumor, suggesting a multifaceted impact on cancer dynamics. Understanding these mechanisms is crucial for developing innovative treatments that could leverage gut microbiota modulation, potentially offering a novel and less invasive approach to combating CRC.

Emerging therapeutic strategies

The evolving understanding of the interplay between CRC stem cells, the TME, and gut microbiota opens up new frontiers for therapeutic strategies. Targeting these complex interactions offers a promising avenue for more effective treatments. Recent advancements propose interventions like microbiota modulation, immune therapy tailored to the TME, and drugs targeting stem cell pathways[6,15,16]. These strategies represent a paradigm shift from conventional chemotherapy to more personalized and holistic approaches, aiming to disrupt the supportive network that fuels CRC progression. The potential of these therapies lies not just in their direct anticancer effects, but also in their ability to reshape the tumor landscape, making it less conducive to cancer growth and resistance.

Conclusion

In conclusion, the intricate interplay between CRC stem cells, the TME, and gut microbiota presents a fascinating yet complex puzzle in the realm of CRC research. The insights gleaned from recent studies not only enhance our understanding of CRC pathogenesis but also pave the way for innovative therapeutic approaches (Table 1). Embracing these new paradigms, which focus on targeting the cancer ecosystem as a whole, could significantly improve treatment outcomes. It is imperative that future research continues to unravel these complex relationships, as they hold the key to unlocking more effective and personalized CRC therapies.

Table 1 Microbial influences in colorectal cancer: Species, pathways, and therapeutic potential.
Microbial species
Role in colorectal cancer
Associated molecular pathways
Expression in CRC patients (↑/↓)
Potential therapeutic target (yes/no)
Notes
Ref.
Bacteroides fragilisPromotes tumor growth and inflammationTLR4/NF-κB signaling pathwayYesEnterotoxigenic strains significant[17]
Fusobacterium nucleatumIncreases cell proliferation and adhesionFadA adhesion, E-cadherin activationYesLinked to tumor progression[18]
Escherichia coli (pks+)Induces genotoxicity and DNA damageColibactin production, DNA double-strand breaksNopks+ strains carry colibactin genes[19]
Faecalibacterium prausnitziiExhibits anti-inflammatory propertiesShort-chain fatty acid production, IL-10 stimulationYesProtective role in gut health[20]
Streptococcus gallolyticusAssociated with tumor developmentUnknownNoCorrelation with CRC, mechanisms unclear[21]
Enterococcus faecalisPromotes oxidative stress and DNA damageProduction of extracellular superoxideYesRole in early-stage CRC[22]
ACKNOWLEDGEMENTS

We would like to thank our colleagues Zhi-Peng Li, Yu-Hua Ruan, and Peng Wang for their review of this manuscript and their support with the data. We also appreciate the reviewers and editorial staff members who contributed to the review and editing of this manuscript.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Cell and tissue engineering

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade A

P-Reviewer: Ventura C S-Editor: Wang JJ L-Editor: A P-Editor: Zhao YQ

References
1.  Novoa Díaz MB, Carriere P, Gentili C. How the interplay among the tumor microenvironment and the gut microbiota influences the stemness of colorectal cancer cells. World J Stem Cells. 2023;15:281-301.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
2.  Ahamad N, Sun Y, Nascimento Da Conceicao V, Xavier Paul Ezhilan CRD, Natarajan M, Singh BB. Differential activation of Ca(2+) influx channels modulate stem cell potency, their proliferation/viability and tissue regeneration. NPJ Regen Med. 2021;6:67.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
3.  Wang H, Tian T, Zhang J. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. Int J Mol Sci. 2021;22.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 179]  [Article Influence: 44.8]  [Reference Citation Analysis (0)]
4.  Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44:222-236.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 165]  [Reference Citation Analysis (0)]
5.  Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35:787-820.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 244]  [Article Influence: 61.0]  [Reference Citation Analysis (0)]
6.  Zheng X, Ma Y, Bai Y, Huang T, Lv X, Deng J, Wang Z, Lian W, Tong Y, Zhang X, Yue M, Zhang Y, Li L, Peng M. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment. Front Immunol. 2022;13:984480.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 23]  [Article Influence: 7.7]  [Reference Citation Analysis (0)]
7.  Xie S, Cai Y, Chen D, Xiang Y, Cai W, Mao J, Ye J. Single-cell transcriptome analysis reveals heterogeneity and convergence of the tumor microenvironment in colorectal cancer. Front Immunol. 2022;13:1003419.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 12]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
8.  Yadav VK, Huang YJ, George TA, Wei PL, Sumitra MR, Ho CL, Chang TH, Wu ATH, Huang HS. Preclinical Evaluation of the Novel Small-Molecule MSI-N1014 for Treating Drug-Resistant Colon Cancer via the LGR5/β-catenin/miR-142-3p Network and Reducing Cancer-Associated Fibroblast Transformation. Cancers (Basel). 2020;12.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 13]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
9.  Petitprez F, Meylan M, de Reyniès A, Sautès-Fridman C, Fridman WH. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol. 2020;11:784.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 127]  [Cited by in F6Publishing: 360]  [Article Influence: 72.0]  [Reference Citation Analysis (0)]
10.  Xu C, Yan L, Guan X, Wang Z, Wu J, Lv A, Liu D, Liu F, Dong B, Zhao M, Jia L, Tian X, Hao C. Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma. Int J Biol Sci. 2022;18:5038-5055.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 8]  [Reference Citation Analysis (0)]
11.  Qu R, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, Zhang Z, Fu W. Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer. Adv Sci (Weinh). 2023;10:e2205563.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 41]  [Article Influence: 20.5]  [Reference Citation Analysis (0)]
12.  Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol. 2023;20:429-452.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 174]  [Reference Citation Analysis (0)]
13.  Rebersek M. Gut microbiome and its role in colorectal cancer. BMC Cancer. 2021;21:1325.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 160]  [Article Influence: 40.0]  [Reference Citation Analysis (0)]
14.  Francescangeli F, De Angelis ML, Zeuner A. Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer. Nutrients. 2019;11:2936.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 24]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
15.  Han JX, Tao ZH, Wang JL, Zhang L, Yu CY, Kang ZR, Xie Y, Li J, Lu S, Cui Y, Xu J, Zhao E, Wang M, Chen J, Wang Z, Liu Q, Chen HM, Su W, Zou TH, Zhou CB, Hong J, Chen H, Xiong H, Chen YX, Fang JY. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. Nat Microbiol. 2023;8:919-933.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 67]  [Reference Citation Analysis (0)]
16.  Zhang Q, Zhao Q, Li T, Lu L, Wang F, Zhang H, Liu Z, Ma H, Zhu Q, Wang J, Zhang X, Pei Y, Liu Q, Xu Y, Qie J, Luan X, Hu Z, Liu X. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8(+) T cell immunity. Cell Metab. 2023;35:943-960.e9.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 110]  [Reference Citation Analysis (0)]
17.  Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317-328.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 503]  [Cited by in F6Publishing: 554]  [Article Influence: 50.4]  [Reference Citation Analysis (0)]
18.  Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207-215.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1659]  [Cited by in F6Publishing: 1789]  [Article Influence: 149.1]  [Reference Citation Analysis (0)]
19.  Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 231]  [Cited by in F6Publishing: 253]  [Article Influence: 23.0]  [Reference Citation Analysis (0)]
20.  Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039-1048.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 658]  [Cited by in F6Publishing: 844]  [Article Influence: 105.5]  [Reference Citation Analysis (0)]
21.  Pasquereau-Kotula E, Martins M, Aymeric L, Dramsi S. Significance of Streptococcus gallolyticus subsp. gallolyticus Association With Colorectal Cancer. Front Microbiol. 2018;9:614.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 53]  [Cited by in F6Publishing: 91]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
22.  Strickertsson JA, Desler C, Martin-Bertelsen T, Machado AM, Wadstrøm T, Winther O, Rasmussen LJ, Friis-Hansen L. Enterococcus faecalis infection causes inflammation, intracellular oxphos-independent ROS production, and DNA damage in human gastric cancer cells. PLoS One. 2013;8:e63147.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 60]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]